8-KEarnings & ResultsExhibits & Filings

ELI LILLY & Co 8-K Report, Financial Results (Jul 21, 2006)

Filed July 21, 2006For Securities:LLY

Summary

Eli Lilly & Company (LLY) filed an 8-K on July 21, 2006, to announce its financial results for the quarter and six-month period ended June 30, 2006. The report highlights the company's use of non-GAAP financial measures, specifically adjusted net income and adjusted diluted earnings per share, to provide a clearer view of ongoing operations. These adjusted figures exclude significant one-time charges from prior periods, such as a product liability charge from Q2 2005 and asset impairment, restructuring, and accounting change charges from Q4 2005, allowing for more meaningful period-over-period comparisons. The company also provided financial expectations for the third quarter and full year 2006, emphasizing that these projections, like historical adjusted figures, may exclude potential future material, unusual items. This approach aims to offer investors a better understanding of the company's core business performance and operational trends, while acknowledging that the forward-looking guidance is subject to variability.

Key Highlights

  • 1Announcement of Q2 and H1 2006 financial results, including income statements.
  • 2Company utilizes non-GAAP financial measures (adjusted net income, adjusted EPS) for performance comparison.
  • 3Adjusted figures exclude significant prior-period charges (Q2 2005 product liability, Q4 2005 asset impairment/restructuring/accounting change) to enhance comparability.
  • 4Provides financial expectations for Q3 and full-year 2006.
  • 5Guidance may exclude potential future material, unusual items, such as proposed European site closures.
  • 6Press release and related financial statements are furnished as Exhibit 99 to the 8-K filing.
  • 7Management uses non-GAAP measures internally for performance evaluation and resource allocation.

Frequently Asked Questions

This 8-K filing primarily serves to announce Eli Lilly's financial results for the second quarter and the first six months of 2006, along with providing forward-looking financial guidance for the third quarter and the full year 2006. It also details the company's use of non-GAAP financial measures for reporting.

Eli Lilly uses non-GAAP measures like adjusted net income and adjusted earnings per share to provide investors with a more meaningful view of its ongoing operations. By excluding certain charges (like product liability or restructuring costs) that are volatile, difficult to predict, or substantial, the company aims to enable clearer period-over-period comparisons and identify operating trends that might otherwise be masked.

To ensure a more meaningful comparison of 2005 results with 2006 projections, the company excluded the second quarter 2005 product liability charge. Additionally, it excluded charges recognized in the fourth quarter of 2005, specifically asset impairment, restructuring, and other special charges, as well as the cumulative effect of an accounting change related to FIN 47 for conditional asset retirement obligations.

No, the 2006 financial guidance provided by Eli Lilly may not include the impact of certain future material, unusual items. The company notes that prospective quantification of such items is often not feasible, providing an example of potential charges related to proposals for closing European sites.